Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DR 10624

Next Previous
Drug Profile

DR 10624

Alternative Names: DR-10624

Latest Information Update: 09 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zhejiang Doer Biologics
  • Class Antihyperglycaemics; Hepatoprotectants; Immunoglobulin Fc fragments; Obesity therapies; Recombinant fusion proteins
  • Mechanism of Action Fibroblast growth factor 21 agonists; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypertriglyceridaemia; Non-alcoholic steatohepatitis
  • Phase I/II Obesity
  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 01 Jul 2025 Shanghai Zhongshan Hospital plans clinical trial for Hypertriglyceridaemia and Carotid stenosis (In adults) in China (SC, Injection), (NCT07050134)
  • 23 Apr 2025 Phase-II clinical trials in Non-alcoholic steatohepatitis (SC) prior to April 2025
  • 23 Apr 2025 Pharmacodynamics data from a preclinical study in Non-alcoholic steatohepatitis released by Zhejiang Doer Biologics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top